To date, recent studies revealed that GABPB1L and TRIM28 had the potential to be the therapeutic target for TERT promoter mutation‐positive patients with glioblastoma and bladder cancer, respectively.21, 22. This evidence concerns the gene TERT and urinary bladder cancer.